Sign in
SuspendedPhase 2

Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy.

Key facts

Who runs it
UNICANCER
Where
France16 sites in 1 countryChoose a country to see its sites
Status
Suspended
Phase
Phase 2
People taking part
80 people enrolled
Started
28 Oct 2020
Expected to end
31 Dec 2026
Type of study
Interventional, 2 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Riluzole
  • Placebo Oral Tablet
Record updated
20 May 2026
Why it stopped
Lack of treatment, sponsor decision.

Who can take part

Age
18 years and older
Sex
Women and men
Healthy volunteers
Cannot take part

The registry criteria, word for word

Show all 23 criteriaShow less

Who can take part

  • Patients aged ≥ 18 years old,
  • Eligible patient starting adjuvant oxaliplatin-based chemotherapy (6-12 cycles, Simplified FOLFOX4) for stage II/III colorectal cancer,
  • Histological or cytological confirmation of colorectal cancer,
  • Performance status (ECOG) ≤2,
  • Normal hematological function (ANC ≥1.5 x 10⁹/L; platelets count ≥100 x 10⁹/L; hemoglobin ≥9.0 g/dL),
  • Normal hepatic function: total bilirubin ≤1.5 x upper limit of normal (ULN) (unless documented Gilbert's syndrome); aspartate aminotransferase (ASAT) and alanine aminotransferase (ALAT) ≤3 x ULN, and gamma-glutamyltransferase (GGT) ≤3 x ULN,
  • Normal renal function: serum creatinine ≤1.5 x ULN,
  • Normal cardiac function: ECG,
  • Patients affiliated to the French national health insurance,
  • Patient must have signed a written informed consent form prior to any study specific procedures,
  • French language comprehension,
  • Patient is willing and able to comply with the protocol for the duration of the study including undergoing treatment and scheduled visits and examinations including follow up

Who cannot take part

  • Previous neurotoxic chemotherapy treatment,
  • Dependence on alcohol or drugs,
  • Metastatic cancer,
  • Patients with chronic obstructive pulmonary disease,
  • Patients with known allergy or severe hypersensitivity to riluzole or any of the study drug excipients,
  • Psychotic disorders,
  • Diagnosis of neuropathy,
  • EORTC QLQ-CIPN20 sensory score >6,
  • ALAT/ASAT elevated more than 3 times the normal value,
  • Women pregnant or breastfeeding,
  • Patients undergoing a measure of legal protection (trusteeship, guardianship ...)

This trial has no sites in United States.

It has sites in one country. Choose a country to see its sites.

About the trial

What the trial wants to find out

It is a phase II trial, randomized, parallel, double blind, multicenter, comparing riluzole versus placebo.

Read full original descriptionShow less

The trial population is composed of patients ≥18 years old that have developed stage II/III colorectal cancer and are eligible for Simplified FOLFOX4 (6-12 cycles) adjuvant chemotherapy.

The primary objective is to assess the preventive efficacy of riluzole on the severity of oxaliplatin-induced peripheral neuropathy during the Simplified FOLFOX4 adjuvant chemotherapy of stage II/III colorectal cancers.

The 2 groups in the trial

  • RiluzoleTreatment being tested

    The patient will be taken one tablet twice a day, in the morning and in the evening during the meal (12h interval). The medication is taken during the 14 days of each chemotherapy cycle, beginning 7 days before the start of chemotherapy and ending 2 weeks after the start of last cycle of chemotherapy (25 weeks). The treatment ends with the cessation of chemotherapy (visit V3 or anticipated stop).

  • PlaceboPlacebo, for comparison

    Posology, administration and duration of treatment will be equivalent to riluzole group.

    Treatment: Placebo Oral Tablet

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Effectiveness Assessment of Riluzole in the Prevention of Oxaliplatin-induced Peripheral Neuropathy: A Phase II Randomized Study by UNICANCER With the Cooperation of AFSOS
Publications
Record updated
20 May 2026